Trial Profile

A Phase II Trial of Docetaxel Plus ASA404 as Second-Line Therapy in Patients With Advanced Urothelial Carcinoma: Hoosier Oncology Group GU09-144.

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 21 Aug 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vadimezan (Primary) ; Docetaxel
Indications Urogenital cancer
Focus Therapeutic Use

Most Recent Events

17 Aug 2015 Status changed from suspended to withdrawn prior to enrolment, as reported by ClinicalTrials.gov.
20 Aug 2010 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
03 Apr 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com